Drug Profile
BIO 203 - Biophytis
Alternative Names: BIO203Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Biophytis
- Class Eye disorder therapies
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Age-related macular degeneration in France (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in France (PO)
- 01 Jul 2016 Preclinical trials in Age-related macular degeneration in France (PO)